Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02104427 · ClinicalTrials.gov registry record · Phase 2
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
A Phase 2 study, sponsored by GPCR Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT02104427 is a Phase 2 study that has completed, run by GPCR Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT02104427, a Phase 2 study, has completed, sponsored by GPCR Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
Interventions
- DRUG TG-0054 combined with G-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-02 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02104427
The ClinicalTrials.gov registry entry for NCT02104427 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GPCR Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TG-0054 combined with G-CSF is the first listed.
NCT02104427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02104427 about?
NCT02104427 is a clinical study titled "PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients". This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
What is the current status of trial NCT02104427?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2015-02. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02104427?
The interventions under investigation include: TG-0054 combined with G-CSF (DRUG).
Who is sponsoring clinical trial NCT02104427?
This trial is sponsored by GPCR Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.